Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | FOR46 |
| Synonyms | |
| Therapy Description |
FOR46 (FG-3246) is an antibody-drug conjugate (ADC) comprising a CD46 monoclonal antibody linked to MMAE, which potentially inhibits tumor growth (PMID: 40138611). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| FOR46 | FOR-46|ADC FOR46|CD46-ADC FOR46|FG-3246|FG3246 | FOR46 (FG-3246) is an antibody-drug conjugate (ADC) comprising a CD46 monoclonal antibody linked to MMAE, which potentially inhibits tumor growth (PMID: 40138611). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03575819 | Phase I | FOR46 | A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Completed | USA | 0 |
| NCT06842498 | Phase II | FOR46 | A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Recruiting | USA | 0 |
| NCT03650491 | Phase I | FOR46 | A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | Completed | USA | 0 |